Abiomed Sales Boosted By Impella Reorders In Fiscal Q4
This article was originally published in The Gray Sheet
Executive Summary
Abiomed sales advanced 17% to $23 million for the most recent fiscal quarter, driven by Impella percutaneous cardiac assist system reorders, despite 68% slower growth in the customer base
You may also be interested in...
Abiomed Impella 5.0
Firm gains 510(k) clearance for its Impella 5.0 and Impella LD minimally invasive catheter-based circulatory support pumps, which provide circulatory support for up to six hours. The pumps are driven by the same console as the Impella 2.5, which was cleared by FDA in June 2008, but provide up to five liters of blood flow per minute instead of 2.5 1("The Gray Sheet" June 9, 2008, p. 20). While the 5.0 version is implanted via the femoral artery (as is the 2.5 model), the LD model is inserted through the chest. The devices can provide a therapeutic benefit from "ventricular unloading," the company explains (2"The Gray Sheet" Nov. 17, 2008, p. 5)
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.